Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 328
Filter
1.
Tumour Biol ; 23(2): 70-5, 2002.
Article in English | MEDLINE | ID: mdl-12065844

ABSTRACT

Concentrations of soluble c-erbB-2 were determined in the sera of 64 patients with distant metastasis from advanced breast cancer receiving second-line hormone or chemotherapy in comparison to 35 breast cancer patients without detectable recurrent disease and 17 healthy blood donors. The sera of non-metastatic breast cancer patients contained s-erbB-2 concentrations similar to those of healthy blood donors. Patients with distant metastasis from advanced breast cancer had significantly higher values of s-erbB-2 in comparison to patients with non-disseminated disease (mean: 59.6 vs. 11.6 U/ml; p = 0.022). A significant correlation was observed between s-erbB-2 serum levels and serum LDH concentrations (p < 0.001), levels of alkaline phosphatase (p < 0.001), and the presence of hepatic metastasis (p = 0.001). Time to tumor progression was significantly shorter in patients with s-erbB-2 levels above 40 U/ml (mean: 23.4 vs. 56.7 months; p = 0.002). Furthermore, breast cancer patients with hepatic metastasis and those with elevated s-erbB-2 serum levels above 40 U/ml had limited response to hormone or chemotherapy. Non-responders had significantly higher s-erbB-2 levels (mean: 270.3, range: 42-500 U/ml;) compared with the responder group (mean: 23.1, range: 0-149 U/ml; p < 0.001). Logistic regression analysis indicated that elevated s-erbB-2 serum levels above 40 U/ml independently predicted an unfavorable response to second-line hormone or chemotherapy in patients with advanced metastatic breast cancer.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/blood , Breast Neoplasms/blood , Carcinoma/secondary , Chemotherapy, Adjuvant , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Liver Neoplasms/secondary , Neoplasm Proteins/blood , Receptor, ErbB-2/blood , Adult , Alkaline Phosphatase/blood , Antineoplastic Agents, Hormonal/pharmacology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma/blood , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cyclophosphamide/pharmacology , Disease Progression , Female , Fluorouracil/administration & dosage , Fluorouracil/pharmacology , Genes, erbB-2 , Humans , L-Lactate Dehydrogenase/blood , Liver Neoplasms/blood , Methotrexate/administration & dosage , Methotrexate/pharmacology , Middle Aged , Neoplasm Proteins/genetics , Predictive Value of Tests , Prognosis , Receptor, ErbB-2/genetics , Salvage Therapy , Treatment Outcome
2.
Anticancer Res ; 21(4B): 2995-3000, 2001.
Article in English | MEDLINE | ID: mdl-11712800

ABSTRACT

Concentrations of soluble CD44 standard (sCD44std) and CD44 variant 6 (sCD44v6) isoforms were determined in the sera of 59 patients with distant metastasis from breast cancer receiving second line hormone- or chemotherapy, in comparison to 46 breast cancer patients without detectable recurrent disease and 21 healthy blood donors. The sera of non-metastatic breast cancer, patients contained sCD44std and sCD44v6 concentrations similiar to those of healthy blood donors. In sera of patients with distant metastasis from recurrent breast cancer the median values of sCD44std and sCD44v6 were significantly higher (sCD44std: 502 ng/ml, p=0.03; sCD44v6: 193 ng/ml, p = 0.002) in comparison to healthy blood donors and patients with non-metastatic disease (p<0.001 for both parameters). A significant correlation was observed between sCD44v6 serum concentrations and the number of metastasized organs (p=0.0018), serum LDH concentrations (p<0.0001), tumor grading (p=0.025) and the presence of hepatic metastasis (p=0.028). Furthermore, sCD44v6 expression was associated with the patient's responsiveness to second line hormone- or chemotherapy. Non-responders had significantly higher sCD44v6 levels compared with the responder group (median: 447 ng/ml vs 171 ng/ml; p=0.0007). Logistic regression analysis indicated that sCD44v6 serum levels above 250 ng/ml (p =0.033) and the presence of hepatic metastasis (p=0.009) were independent factors predicting an unfavourable response to therapy.


Subject(s)
Antigens, Neoplasm/blood , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/blood , Breast Neoplasms/blood , Glycoproteins/blood , Hyaluronan Receptors/blood , Neoplasm Metastasis/diagnosis , Adult , Aged , Alkaline Phosphatase/blood , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , L-Lactate Dehydrogenase/blood , Liver Neoplasms/blood , Liver Neoplasms/secondary , Logistic Models , Methotrexate/administration & dosage , Middle Aged , Neoplasm Proteins/blood , Organ Specificity , Predictive Value of Tests , Remission Induction , Risk Factors , Solubility , Treatment Outcome
3.
Int J Cancer ; 91(2): 225-30, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11146449

ABSTRACT

After adoptive transfer of pre-activated lymphocytes into the operation cavity of glioma patients, tumor regression and improved survival have been reported in some patients. Results were most impressive when bispecific antibodies with tumor x CD3 specificity were also applied. In this study, we attempted to avoid time-consuming pre-activation procedures for adoptively transferred cells by using a combination of bispecific antibodies directed to the EGF receptor (EGFR) on tumor cells and to CD3 and CD28 on T cells. Eleven patients with high-grade malignant glioma received 3 injections of 2 bispecific antibody fragments (EGFR x CD3 and EGFR x CD28) together with freshly isolated autologous lymphocytes via an Ommaya reservoir. Intracavitary fluid aspirated during immunotherapy was examined for markers of T-cell activation. Increased levels of soluble IL-2 receptor and TNF-alpha were detected in the intracavitary fluid of all patients tested. Two of the 11 treated patients experienced a beneficial response to therapy as defined by a transient contrast enhancement in subsequent MRI scans and prolonged survival. Side effects were transient and consisted of fever, nausea, headache and aggravation of pre-existing neurologic deficits. These adverse effects were most likely due to the antibody construct containing anti-CD3 specificity. Two patients developed cerebral edema and required steroid treatment.


Subject(s)
Antibodies, Bispecific/therapeutic use , CD28 Antigens/immunology , CD3 Complex/immunology , ErbB Receptors/immunology , Glioma/therapy , Immunotherapy, Adoptive , Lymphocyte Activation , T-Lymphocytes/immunology , Adult , Female , Glioma/immunology , Glioma/pathology , Humans , Male , Middle Aged , Tumor Cells, Cultured
4.
Eur J Med Res ; 5(6): 273-6, 2000 Jun 20.
Article in English | MEDLINE | ID: mdl-10882644

ABSTRACT

Retinoids are highly active for the treatment of acute promyelocytic leukemia, but have effects on many different types of normal and transformed cells. CD95 is a member of the TNF-receptor superfamily and can mediate apoptosis. In this study, we screened a series of 7 myeloid and 12 lymphoid cell lines for the expression of CD95 and for the induction of CD95 by retinoids. A differential response was observed: in 3/7 myeloid cell lines a significant down-regulation of CD95 happened which correlated with the induction of differentiation. A significant induction of CD95 was observed in 4/ 12 lymphoid lines (2 HHV8+ cell lines, one Burkitt line and another lymphoma line). The modulation of CD95 was both time- and dose- dependent (maximum reached after 3-5 days of culture with 10-6 M retinoid). The 3 retinoid compounds studied (all-trans retinoic acid, 9-cis retinoic acid and 13-cis retinoic acid) had comparable activity. Taken together, we describe a new mode of induction of CD95 in lymphoma cells. More work is needed to define the functional consequences of these changes in CD95 surface expression.


Subject(s)
Leukemia , Retinoids/pharmacology , fas Receptor/biosynthesis , Apoptosis/drug effects , Apoptosis/immunology , Humans , Leukemia/drug therapy , Leukemia/immunology , Leukemia/pathology , Retinoids/therapeutic use , Tumor Cells, Cultured
5.
Bone Marrow Transplant ; 25(3): 237-41, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10673693

ABSTRACT

IL-10 is a potent immunosuppressant which inhibits allo-antigen-specific T cell responses. In addition, IL-10 is a strong endogenous anti-inflammatory cytokine. To investigate the role of IL-10 in the induction of acute GVHD following allogeneic bone marrow transplantation (BMT) we performed a prospective study on spontaneous IL-10 production by peripheral blood mononuclear cells (PBMNC) in 84 patients admitted for allogeneic BMT. High spontaneous IL-10 production by PBMNC at the time of admission and prior to any preparative treatment correlated with a subsequent low incidence of GVHD and transplant-related mortality (8%), as compared to patients with low or intermediate IL-10 production (50%, P < 0. 01). Our data demonstrate the prognostic significance of increased IL-10 production in BMT patients and suggest a major role of IL-10 in maintaining immunobalance in the setting of allogeneic BMT. Bone Marrow Transplantation (2000) 25, 237-241.


Subject(s)
Bone Marrow Transplantation , Interleukin-10/biosynthesis , Interleukin-10/pharmacology , Adolescent , Adult , Cell Culture Techniques , Female , Graft vs Host Disease/etiology , Humans , Interleukin-10/blood , Leukemia/blood , Leukemia/metabolism , Leukemia/therapy , Leukocytes, Mononuclear/chemistry , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Prognosis , Prospective Studies , Time Factors , Transplantation, Homologous
6.
Leukemia ; 13(11): 1864-72, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10557064

ABSTRACT

With the growing understanding of cytostatic drug-induced programmed cell death new drug-resistance mechanisms based on the altered ability of cells to die by apoptosis have been defined. At first, the sensitive and P-glycoprotein (P-gp)-related resistant cell lines were tested to induce apoptosis by a non-P-gp transported drug, such as cytosine arabinoside (ara-C). It was demonstrated that ara-C induces apoptosis in sensitive as well as in P-gp-related resistant cell lines, as expected. Furthermore, the role of bcl-2 and bcl-xL apoptosis inhibitors as well as bax expression (apoptosis inducer) in human sensitive leukemic cell lines (CCRF-CEM and HL-60) as compared to their resistant variants such as CCRF-CEM/ACT400, CCRF-CEM/VCR1000, HL-60/IDA40, HL-60/DNR250 was evaluated. In addition to the P-gp-related resistance, a possible multidrug resistance-associated protein (MRP) and the lung resistance protein (LRP)-related resistance were assessed by flow cytometry using the monoclonal antibodies 4E3.16, MRPr1 and LRP56. Furthermore, the function of P-gp was determined with the rhodamine-123 (R-123) accumulation test. Bcl-2 and bax were analyzed by both flow cytometry and ECL Western blot, bcl-xL by ECL-Western blot alone. Comparison of the two sensitive cell lines demonstrated different bcl-2, bax and bcl-xL patterns. The common characteristic was the increased expression of one of the apoptosis inhibitor proteins, such as bcl-2 or bcl-xL. The sensitive CCRF-CEM showed a high bax level, where a decrease of about 75% in resistant variants was measured. Compared to their sensitive counterpart HL-60, a low bax expression was analyzed, which increased in the resistant variant. The common characteristic of all resistant cell lines was the decreased expression of bax compared to bcl-2 or bcl-xL. In the P-gp-related resistant HL-60/DNR250 only an increase in bcl-xL was seen, whereas in the LRP-expressing as well as P-gp and MRP negative resistant HL-60/IDA40 both apoptotic inhibitor proteins bcl-2 and bcL-xL showed maximum increase, compared to the other resistant cell lines. The P-gp-related resistant cell lines CCRF-CEM/ACT400 and CCRF-CEM/VCR1000 also showed an increased expression of both bcl-2 and bcl-xL. Summarizing these results, it was shown that the examined sensitive human leukemic cell lines and their resistant variants demonstrated a different pattern of markers for preventing and promoting apoptosis. An association between P-gp and possible LRP-expressing leukemic cells as well as apoptosis-preventing markers (bcl-2, bcl-xL) seems to exist. The clinical relevance of the coexpression of various resistance mechanisms remains to be confirmed in large leukemia patient groups.


Subject(s)
Drug Resistance, Neoplasm , Leukemia/metabolism , Leukemia/pathology , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins/biosynthesis , ATP Binding Cassette Transporter, Subfamily B/metabolism , ATP-Binding Cassette Transporters/analysis , Annexin A5/analysis , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Blotting, Western , Cytarabine/pharmacology , Drug Screening Assays, Antitumor , Flow Cytometry , Gene Expression , HL-60 Cells , Humans , Inhibitory Concentration 50 , Microscopy, Fluorescence , Multidrug Resistance-Associated Proteins , Neoplasm Proteins , Tumor Cells, Cultured , Vault Ribonucleoprotein Particles , bcl-2-Associated X Protein , bcl-X Protein
7.
Leukemia ; 13(11): 1873-80, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10557065

ABSTRACT

Glucocorticoids and fludarabine are able to induce typical features of apoptosis in CLL lymphocytes. Cysteinyl aspartate specific proteases (caspases) play a key biochemical role in the apoptotic pathway. Caspase activation following cytotoxic stimuli leads to highly specific proteolytic cleavage of functionally important cellular enzymes. One of them is poly ADP-ribose) polymerase (PARP). To some extent caspase activation seems to be under the control of the Bcl-2 family of interacting proteins. We determined the role of Bcl-2-family proteins Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic), activation of caspase-3 (CPP32/Yama) and activation of PARP in CLL apoptosis. All 21 analyzed CLL samples expressed Bcl-2 and Bax. Four of 13 (31%) samples with a low Bcl-2/Bax ratio exhibited in vitro prednisolone resistance, whereas eight of nine (88%) samples with a high Bcl-2/Bax ratio were in vitro resistant (

Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Caspases/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/enzymology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Aged , Aged, 80 and over , Amino Acid Chloromethyl Ketones/pharmacology , Antineoplastic Agents/antagonists & inhibitors , Antineoplastic Agents/therapeutic use , B-Lymphocytes/drug effects , B-Lymphocytes/enzymology , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Benzamides/pharmacology , Blotting, Western , Caspase 3 , Caspase Inhibitors , DNA Fragmentation/drug effects , Drug Screening Assays, Antitumor , Enzyme Activation/drug effects , Female , Gene Expression/drug effects , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Male , Middle Aged , Poly(ADP-ribose) Polymerase Inhibitors , Poly(ADP-ribose) Polymerases/metabolism , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Tumor Cells, Cultured , bcl-2-Associated X Protein
8.
Ann Hematol ; 78(10): 449-55, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10550555

ABSTRACT

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is known to stimulate granulocytes, monocytes, and macrophages. We studied the effect of GM-CSF on (clonal) bone marrow (BM) cells obtained from AML patients after 7 days of culture in vitro: BM samples were obtained from 19 AML patients at diagnosis (DIA), from two patients with persisting disease (PERS), from eight patients in complete remission (CR), and from 12 healthy donors. Flow-cytometric comparison of differentiated, CD 15-positive cells or of CD34-positive blast cells before and after cultivation showed that the proportion of CD15-positive cells was increased in nine of 12 healthy BM samples, in 14 of 19 cases at DIA, in one of three cases during PERS, and in five of six cases in CR of AML. The proportion of CD34-positive cells was increased in one of 12 healthy BM samples, in seven of 19 cases at DIA, in one of two cases during PERS, and in three of seven cases in CR of AML. Southern blot analysis (SBA) performed in six cases during the course of AML, before and after cell culture, showed that clonal DNA increased after GM-CSF treatment in three of five cases studied at DIA, in six of nine cases studied in CR, in the one case studied at PERS, and in the one studied at relapse (REL). In one case of trisomy 8 at DIA a normal karyotype was demonstrated in CR. However, after 7 days of cultivation of the cells in GM-CSF the trisomy 8 was detected in two of 17 metaphases isolated from colony-cells from methylcellulose cultures. Our data show that a 7-day treatment of BM cells with GM-CSF induced a differentiation of healthy and leukemic BM cells in the great majority of cases. An enrichment of CD34-positive cells was not achieved in healthy BM samples. However, in 70% of the cases in CR and in 30% of the cases at DIA of AML, clonal CD34-positive cells were enriched. This means that GM-CSF stimulates ('primes') leukemic cell growth in vitro.


Subject(s)
Bone Marrow Cells/pathology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Leukemia, Myeloid/pathology , Antigens, CD34/analysis , Cell Differentiation/drug effects , Cell Division/drug effects , Clone Cells/cytology , Clone Cells/drug effects , Granulocytes/cytology , Granulocytes/immunology , Hematopoietic Stem Cells/immunology , Humans , Leukemia, Myeloid/diagnosis , Lewis X Antigen/analysis
9.
Anticancer Res ; 19(4A): 2421-5, 1999.
Article in English | MEDLINE | ID: mdl-10470169

ABSTRACT

Human chorionic gonadotropin (HCG) is expressed in germ cell tumors and urothelial, breast, lung and colon cancers. The aim of the study was to investigate if the determination of HCG in comparison with CEA is able to discriminate between malignant and benign effusions. Effusion and partially serum samples of 61 patients with benign (g.i., heart/kidney isnuff.) and 116 patients with malignant diseases (g.i., gynec., lung, misc., CUP) were investigated. HCG was specifically determined by an IRMA using 2 monoclonal antibodies, CEA by a conventional double Ab RIA. Cytological staining was preformed using the Pappenheim-method on cytospin preparations. Significant differences (p < 0.001) were found for HCG between benign and malignant ascitic effusions with the best discrimination at 5 IU/l (ROC) and an overall sensitivity of 31.3% (spec. vs benign eff. 93.4%) increasing in subgroups from hematol. (5.8%) < misc. (31.3%) < gynec. (32.1%) < g.i. (36%) < lung (38.1%) to CUP (50%). CEA also showed significant differences between benign and malignant total and ascitic effusions, and weaker for the pleural subgroup (cutoff 9 ng/ml) with a total sensitivity of 44.6% (sp = 100%) increasing from misc. (30.8%) < lung (47.1%) < CUP (50%) < gynec. (60%) < g.i. (60.9%). Comparative cytology and TM determinations increased the positiverate of cytology (45.2%) to 58.3% for either cytology or HCG positive cases, or to 61.6% for either cytology or CEA positive cases. For the combined determination of cytologoy and HCG and CEA, the overall TM positive rate for 33 cytology-pos. cases was 78.8%, but in 40 cytology-negative cases 37.5% for TM positive cases. In conclusion HCG is useful in ascitic > pleural effusions with high specificity (90% at 5 IU/l) but low sensitivity of 31% increasing in g.i., lung and gynecologic cases, CEA a more general TM with higher sensitivity of 45% increasing in g.i., gynecologic and lung cases (sp. 100% at 9 ng/ml) both adding significantly to cytology-negative effusions.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoembryonic Antigen/analysis , Chorionic Gonadotropin/analysis , Exudates and Transudates/chemistry , Neoplasms/diagnosis , Biomarkers, Tumor/blood , Carcinoembryonic Antigen/blood , Chorionic Gonadotropin/blood , Diagnosis, Differential , Female , Gastrointestinal Diseases/blood , Gastrointestinal Diseases/diagnosis , Humans , Kidney Diseases/blood , Kidney Diseases/diagnosis , Male , Neoplasms/blood , Neoplasms/physiopathology , ROC Curve , Sensitivity and Specificity
10.
Infection ; 27(2): 114-7, 1999.
Article in English | MEDLINE | ID: mdl-10219641

ABSTRACT

Human parvovirus B19 can persist in immunocompromised patients and may produce severe clinical illness. In this retrospective study the incidence of B19-associated infections in bone marrow transplant patients was investigated. During 1 year 60 patients received bone marrow grafts (eight autografts and 52 allogeneic transplantations). In case of early onset, atypical or steroid-resistant erythrodermia the patients' blood and/or tissue specimens were screened for B19 infection by polymerase chain reaction (PCR). Additionally, specimens of patients with severe organ failure were tested. A total of 64 PCRs was performed in 27 patients. Seven patients with erythrodermia and one with vulvovaginitis proved to be PCR positive. In patients with organ failure B19 DNA was detected in the myocardium and liver. The incidence of B19 infections in this cohort was 15% and the B19-associated mortality rate 7%. In conclusion, parvovirus B19-associated infections may be more common in immunocompromised patients than previously anticipated.


Subject(s)
Bone Marrow Transplantation , Parvoviridae Infections/epidemiology , Parvovirus B19, Human/isolation & purification , Adolescent , Adult , Cohort Studies , DNA, Viral/isolation & purification , Female , Germany/epidemiology , Humans , Immunocompromised Host , Incidence , Male , Middle Aged , Parvoviridae Infections/immunology , Parvovirus B19, Human/genetics , Polymerase Chain Reaction , Retrospective Studies
11.
Int J Cancer ; 80(1): 138-44, 1999 Jan 05.
Article in English | MEDLINE | ID: mdl-9935244

ABSTRACT

The ability of bispecific antibodies with anti-tumor x anti-CD3 specificity to mediate the killing of tumor cells by activated T cells has been demonstrated in many in vitro experiments. Moreover, long-term survival of lymphoma-bearing mice has been observed after treatment with such reagents. The therapeutic effect of bispecific antibodies in solid-tumor models has been less impressive, in particular if fragmented antibodies were used to avoid systemic T-cell activation by bispecific constructs binding to Fc-receptor-positive cells. Here we report that bispecific anti-tumor x anti-CD3-fragments markedly inhibit intraperitoneal as well as pulmonary tumor growth in mice inoculated with B16 melanoma cells, resulting in the long-term survival of animals. Therapeutic success critically depends on the number of recruitable effector cells at the site of tumor growth. A second bispecific construct triggering the co-stimulatory CD28-molecule on the T-cell surface increased tumor-cell killing in vitro and in vivo, despite rather low avidity of this reagent to mouse T cells. Finally, long-term-surviving animals showed improved survival after i.v. rechallenge with tumor cells, indicating that bispecific antibodies are capable of inducing long-lasting protective immunity.


Subject(s)
Antibodies, Bispecific/therapeutic use , CD28 Antigens/immunology , CD3 Complex/immunology , Lymphocyte Activation , Melanoma, Experimental/immunology , Melanoma, Experimental/therapy , Receptors, Fc/immunology , T-Lymphocytes/immunology , Animals , CD28 Antigens/analysis , Fluorescent Antibody Technique, Direct , Fluorescent Antibody Technique, Indirect , Immunoglobulin Fab Fragments/therapeutic use , Mice , Mice, Inbred C57BL , Receptor-CD3 Complex, Antigen, T-Cell/immunology , Spleen/immunology , Survival Analysis , Time Factors , Tumor Cells, Cultured
12.
Oncol Rep ; 6(2): 455-8, 1999.
Article in English | MEDLINE | ID: mdl-10023021

ABSTRACT

The diagnosis of malignancy in peritoneal and pleural effusions can be difficult, because activated mesothelial cells may resemble malignant cells. P53 mutations are the most frequent genetic changes in human cancer and translate into an overexpression of the p53 protein detectable by immunocytochemistry. In this study, we investigated the sensitivity and specificity of 4 different monoclonal antibodies (moAB) against p53 for the diagnosis of malignancy in effusions. We also compared p53 staining with CEA immunocytochemistry which previous work had established as a specific marker of malignancy in body cavity effusions. Normal and malignant cells from 28 benign and 52 malignant effusions (pleura and ascites) were examined by indirect immuno-alkaline phosphatase method. Four different moAB against p53 (PAB 1801, PAB 240, DO-1 and DO-7) and one moAB against CEA (CEA-84) were used. Antibodies p1801, p240 and DO-1 react with 52-75% of cases of effusions with malignant cells, but also with 38-80% of benign effusions. Only the antibody DO-7 and the CEA moAB show specificity for malignant cells reacting respectively with 20 (55%) of cases. A combination of these 2 markers does not enhance the sensitivity for the detection of tumor cells. No direct correlation between CEA and p53 immunostaining could be established. The sensitivity and specificity of staining p53 in malignant cells by immunocytochemistry depend strongly on the antibody used. Some p53 moAB are positive with reactive cells in ascites and pleural effusions. Currently, p53 staining of expressing cells does not improve the identification of malignant cells in comparison with CEA immunocytochemistry, but may help to screen for patients with p53 mutations.


Subject(s)
Ascites/pathology , Carcinoembryonic Antigen/analysis , Neoplasms/pathology , Pleural Effusion, Malignant/pathology , Pleural Effusion/pathology , Tumor Suppressor Protein p53/analysis , Antibodies, Monoclonal , Breast Neoplasms/pathology , Colonic Neoplasms/pathology , Female , Humans , Lung Neoplasms/pathology , Mesothelioma/pathology , Stomach/pathology
13.
Ann Hematol ; 78(12): 544-54, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10647878

ABSTRACT

The occurrence of second malignancies (SM) is an important late event following the treatment of Hodgkin's disease (HD). We sought to determine the incidence, the risk factors, and the prognosis of SM in our population of patients with HD. A total of 1120 patients diagnosed with HD were registered at six participating institutions in Munich (calendar period 1974-1994). The mean follow-up for the development of SM was 9.1 years. A cumulative treatment score was calculated for both radio- and chemotherapy. The relative and absolute risks of SM were established. All SM were investigated for response to treatment and outcome. We observed 85 SM [eight leukemias, 22 non-Hodgkin's lymphomas (NHL), two plasma cell neoplasias, and 53 solid tumors]. Five patients developed third malignancies. The relative risk of developing a second neoplasm was compared with that within the normal population and was 3.1-fold. The risk varied according to the category of SM. Higher relative risks (20.5 and 25.9-fold), but lower absolute risks were observed for leukemias and non-Hodgkin's lymphomas. Solid tumors had lower relative risks (1.8-fold). Splenectomy increased the risk of SM (relative risk 4.4-fold versus 2.7-fold). The risk of SM did not correlate with the initial treatment (radio- or chemotherapy) and did not decrease with prolonged follow-up. The cumulative intensity of radiotherapy, chemotherapy, or the two modalities combined correlated with the risk of SM. Since some cases occurred early after diagnosis, not all second neoplasms can be considered treatment-associated. After 15 years, an actuarial risk of 11.7% was calculated for all SM, of 1.0% for leukemias, of 3.0% for NHL, and of 7.7% for solid tumors. The prognosis of SM varied between good (thyroid cancer, melanoma: median survival 5+ years), average (breast cancer, NHL), and poor (acute myeloid leukemias, lung cancers: median survival 9 months). With the exception of NHL, second cancers often occurred in topographic relation to the field of previous radiotherapy. Taken together, in our patient population, we observed all three categories of SM (solid tumors, leukemias, NHL). The risk for second leukemias is lower than in previous studies, whereas the risk of second NHL is somewhat higher. We confirm that splenectomy is a possible risk factor for SM. Even after correction for the age-specific cancer incidence, treatment intensity is associated with the development of second malignant tumors. Continued follow-up is mandatory after treatment for HD. Since the prognosis of most SM is unfavorable, early recognition and prevention are of the utmost importance.


Subject(s)
Hodgkin Disease/therapy , Neoplasms, Second Primary/epidemiology , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Germany/epidemiology , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Humans , Incidence , Male , Middle Aged , Multivariate Analysis , Neoplasms, Second Primary/therapy , Risk Factors , Treatment Outcome
14.
Mediators Inflamm ; 7(2): 79-84, 1998.
Article in English | MEDLINE | ID: mdl-9836493

ABSTRACT

Prostaglandin (PG) D2, PGJ2 and delta12-PGJ2 are antiproliferative eicosanoids. We investigated the production of PGD2 by murine bone marrow-derived mast cells (BMMC) taking into consideration metabolism of PGD2 to PGD2 and delta12-PGJ2. PG-metabolites were quantified by high performance liquid chromatography (HPLC) combined with radioimmunoassay (RIA). Stimulated with calcium ionophore A23187 BMMC released eight-fold more PGJ2 and delta12-PGJ2 than PGD2. Conversion of endogenously produced PGD2 to PGJ2 and delta12-PGJ2 proceeded rapidly in contrast to metabolism of exogenously added PGD2. The antiproliferative potency of these prostaglandins is demonstrated in vitro. We conclude that determination of PGD2 production by mast cells must take into consideration rapid conversion to active derivatives, which may play a significant role in growth regulation.


Subject(s)
Bone Marrow Cells/metabolism , Mast Cells/metabolism , Prostaglandin D2/metabolism , Animals , Bone Marrow Cells/drug effects , Calcimycin/pharmacology , Cell Division , Cells, Cultured , HL-60 Cells , Humans , Ionophores/pharmacology , Leukotriene C4/metabolism , Mast Cells/drug effects , Mice , Mice, Inbred BALB C , Prostaglandin D2/analogs & derivatives , Tumor Cells, Cultured
15.
Magn Reson Imaging ; 16(4): 393-404, 1998 May.
Article in English | MEDLINE | ID: mdl-9665550

ABSTRACT

PURPOSE: To implement and evaluate the accuracy of non-invasive temperature mapping using MRI methods based on the chemical shift (CS) and T1 relaxation in media of various heterogeneity during focal (laser) and external thermal energy deposition. MATERIALS AND METHODS: All measurements were performed on a 1.5 T superconducting clinical scanner using the temperature dependence of the water proton chemical shift and the T1 relaxation time. Homogeneous gel and heterogeneous muscle phantoms were heated focally with a fiberoptic laser probe and externally of varying degree ex vivo by water circulating in a temperature range of 20-50 degrees C. Magnetic resonance imaging data were compared to simultaneously recorded fiberoptic temperature readings. RESULTS: Both methods provided accurate results in homogeneous media (turkey) with better accuracy for the chemical shift method (CS:+/-1.5 degrees C, T1:+/-2.0 degrees C). In gel, the accuracy with the CS method was +/-0.6 degrees C. The accuracy decreased in heterogeneous media containing fat (T1:+/-3.5 degrees C, CS: +5 degrees C). In focal heating of turkey muscle, the accuracy was within 1.5 degrees C with the T1 method. CONCLUSION: Temperature monitoring with the chemical shift provides better results in homogeneous media containing no fat. In fat tissue, the temperature calculation proved to be difficult.


Subject(s)
Body Temperature , Joints/physiology , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy/methods , Muscle, Skeletal/physiology , Animals , Image Processing, Computer-Assisted , Phantoms, Imaging , Reproducibility of Results , Swine , Thermography/methods , Turkeys
17.
Biochem Pharmacol ; 55(4): 447-53, 1998 Feb 15.
Article in English | MEDLINE | ID: mdl-9514079

ABSTRACT

Bleomycin and asparaginase are widely used antineoplastic agents which may induce allergic or inflammatory side-effects. Mast cells are implicated as effector cells in allergic and inflammatory responses. The aim of this study was to establish whether bleomycin or asparaginase modulate leukotriene production in vitro and in vivo. Leukotriene C4 (LTC4) production by murine bone marrow-derived mast cells (BMMC) was determined by radioimmunoassay (RIA). Leukotriene production in patients was assessed by determining leukotriene E4 and N-acetyl-leukotriene E4 in urine by means of combined HPLC and RIA. Bleomycin induced an up to 2.1-fold increase in LTC4 production both in unstimulated and in calcium ionophore-stimulated mast cells. In 3 of 7 patients treated with bleomycin, a greater than 2-fold increase in endogenous leukotriene production was observed. This effect was associated with febrile responses and was most pronounced in a patient who developed an Adult Respiratory Distress Syndrome (ARDS). Asparaginase increased leukotriene production up to 10-fold in stimulated but not in unstimulated BMMC. In a patient who developed an anaphylactic reaction after treatment with asparaginase, a pronounced increase in urinary leukotriene concentration was observed. In contrast to bleomycin or asparaginase, a number of other cytostatic agents did not significantly change leukotriene production by BMMC. Our data indicate that some of the inflammatory and allergic side-effects of bleomycin and asparaginase could be mediated by leukotrienes, a possible source of which may be mast cells.


Subject(s)
Antineoplastic Agents/pharmacology , Asparaginase/pharmacology , Bleomycin/pharmacology , Leukotrienes/biosynthesis , Mast Cells/drug effects , Mast Cells/metabolism , Adult , Anaphylaxis/chemically induced , Anaphylaxis/metabolism , Animals , Calcimycin/pharmacology , Drug Hypersensitivity/etiology , Humans , In Vitro Techniques , Inflammation/chemically induced , Ionophores/pharmacology , Leukotriene C4/biosynthesis , Leukotriene E4/analogs & derivatives , Leukotriene E4/urine , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/metabolism , Mast Cells/immunology , Mice , Mice, Inbred BALB C , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/metabolism
18.
Leuk Lymphoma ; 31(5-6): 589-97, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9922050

ABSTRACT

P-glycoprotein(P-gp)- related resistance is one of the major obstacles in treating leukemia patients. Therefore, it is of clinical interest to find new potential modulators and compare their P-gp-modulating efficacy. The present analysis investigated the influence of P-gp modulators, such as verapamil, tamoxifen, droloxifene E, droloxifene Z, SDZ PSC 833 (PSC 833) and dexniguldipine in a leukemic T-cell line (CCRF-CEM) and its P-gp-resistant counterparts (CCRF-CEM/ACT400 and CCRF-CEM/VCR1000). P-gp expression was assessed with an immunocytological technique using the monoclonal antibody 4E3.16. It was characterized as the percentage of P-gp positive cells and also expressed as a D value by using the Kolmogorov Smirnov statistic. The efficacy of P-gp modulators was determined with the rhodamine-123 accumulation test and the MTT test. An in vitro modulator concentration between 0.1 microM and 3 microM was determined, where no genuine antiproliferative effect was apparent. The modulators PSC 833 and dexniguldipine were the significant (p

Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Cyclosporins/pharmacology , Dihydropyridines/pharmacology , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Leukemia, T-Cell/pathology , Neoplasm Proteins/antagonists & inhibitors , Tamoxifen/analogs & derivatives , Tamoxifen/pharmacology , Verapamil/pharmacology , ATP-Binding Cassette Transporters/analysis , Antibodies, Monoclonal/immunology , Cell Division/drug effects , Drug Screening Assays, Antitumor , Humans , Multidrug Resistance-Associated Proteins , Tumor Cells, Cultured/drug effects , Vault Ribonucleoprotein Particles
19.
Haematologia (Budap) ; 29(3): 195-205, 1998.
Article in English | MEDLINE | ID: mdl-10069445

ABSTRACT

UNLABELLED: Acute lymphoid leukemias (ALL) represent malignant clonal expansions of lymphoid hemopoietic cells arrested at different stages of B- or T-cell maturation. We studied surface marker profiles and cloning capability of bone marrow (BM) cells from 22 adult ALL-patients at diagnosis (n = 15) or relapse (n = 7) in agar cultures under different culture conditions in order to develop a screening system for the classification of ALL and the detection of residual leukemia. Immunophenotyping of those 22 BM-samples enabled a classification in B- or T-linear ALL. Colony growth of BM-cells could be obtained in four out of 20 cases of ALL at diagnosis and in one case at relapse. Different stimulating factors and their combinations (GM-CSF; IL-1; IL-2; IL-3; IL-4; IL-6; placenta conditioned media (PCM); Phytohemagglutinin (PHA, 40%) and lipopolisaccaride (LPS, 1.25%)--containing conditioned media ('B-ly'); IL-1+IL-3; IL-1+IL-4; IL-1+IL-6; IL-1+B-ly) did not show an overall significant difference in stimulating ALL-clones. Immunological phenotyping of ALL-clones in these 5 cases could prove the lymphoid leukemic character of the clones obtained. CONCLUSIONS: Our data show that colony growth of ALL-BM-cells is difficult. Nevertheless, in cases where colony growth could be obtained those clones showed the original surface marker profile of the leukemic cells proving the specificity of our colony assay.


Subject(s)
Bone Marrow Cells/pathology , Leukemia, Lymphoid/pathology , Acute Disease , Adult , Agar , Bone Marrow Cells/immunology , Cell Culture Techniques/methods , Clone Cells , Humans , Immunophenotyping , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...